Provided By GlobeNewswire
Last update: Feb 24, 2025
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company’s Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries.
Read more at globenewswire.comNASDAQ:AVIR (7/23/2025, 9:43:16 AM)
3.445
+0.01 (+0.44%)
Find more stocks in the Stock Screener